A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

ClinicalTrials.gov ID: NCT00884312

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00884312. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Single-Arm, Phase 2 Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center, open-label, Phase 2 study of carfilzomib to monitor the safety and efficacy of long-term or continuing carfilzomib therapy for patients who previously completed a primary carfilzomib treatment study.

Study identification

NCT ID: NCT00884312
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Amgen; Industry
Enrollment: 101 participants

Conditions and interventions

Conditions

Interventions

Carfilzomib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 9, 2009 (Actual)
Primary completion: May 17, 2017 (Actual)
Completion: May 17, 2017 (Actual)
Last update posted: May 14, 2018

2009 – 2017

United States locations

U.S. sites: 21
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
Pinnacle Oncology Hematology	Scottsdale	Arizona	85258	—
Tower Cancer Research Foundation	Beverly Hills	California	90211	—
City of Hope National Medial Center	Duarte	California	91010	—
University of California Medical Center	San Francisco	California	94143	—
Colorado Blood Cancer Institute	Denver	Colorado	80218	—
H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida	33612	—
Winship Cancer Institute - Emory University	Atlanta	Georgia	30322	—
Northwestern University	Chicago	Illinois	60611	—
University of Maryland, Greenebaum Cancer Center	Baltimore	Maryland	21201	—
Washington University School of Medicine	St Louis	Missouri	63110-1093	—
John Theurer Cancer Center at Hackensack UMC	Hackensack	New Jersey	07601	—
Weill Cornell Medical College	New York	New York	10021	—
Mount Sinai School of Medicine	New York	New York	10029	—
Gabrail Cancer Center Research	Canton	Ohio	44718	—
The Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203-1632	—
Texas Oncology Cancer Center	Austin	Texas	78731	—
The University of Texas, MD Anderson Cancer Center	Houston	Texas	77030	—
Northwest Cancer Center	Houston	Texas	77090	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00884312, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 14, 2018 · Synced Nov 12, 2026